Successful allogeneic haematopoietic stem cell transplantation in patients with poor-risk leukaemia and prior invasive fungal infection

Mehta, Pankaj; Augustson, Bradley; Krishnamurthy, S; Jacob, Abraham; Roy, Denis; Olliff, J.; Cook, Mark; Craddock, Charles G.; Mahendra, Premini

doi:10.1038/sj.bmt.1704685

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2006

2009

Publication Types

Select...

Article2

Book1

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29 Invasive fungal infections (IFI) with Aspergillus spp are a significant cause of morbidity and mortality after SCT. 30,31 More than half of transplant patients affected by aspergillosis die from their fungal infections. Reactivation in transplant patients has been estimated to be 30-50% and is associated with a poor prognosis.…”

Section: Discussionmentioning

confidence: 99%

Post-transplant infections: single center experience from the developing world

Ullah¹,

Raza²,

Ahmed³

et al. 2008

International Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Post-transplant infections: single center experience from the developing world

Ullah¹,

Raza²,

Ahmed³

et al. 2008

International Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents

Strasfeld¹,

Weinstock²

2006

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Invasive candidiasis and invasive mold infections cause significant morbidity and mortality in the hematopoietic stem cell transplant population, in particular in recipients of allografts. The introduction of a variety of new antifungal compounds over the past decade has focused attention on prophylactic strategies as a means to decrease the burden of invasive fungal infections (IFIs). Until recently, fluconazole has been the standard agent for prophylaxis before and after engraftment. In 2005, the echinocandin micafungin received US FDA approval for prophylaxis against IFIs in stem cell transplant recipients during the neutropenic period prior to engraftment. In patients with substantial risk for invasive mold infection, many centers now use a mold-active antifungal agent (e.g., a triazole such as itraconazole, voriconazole or posaconazole, or an echinocandin) as prophylaxis after engraftment. Several recent studies have highlighted the efficacy of these newer agents in preventing IFIs in these highly immunocompromised patients. This review will discuss current issues in IFI and new agents available for prophylaxis in allogeneic hematopoietic stem cell transplant recipients.

show abstract

Prophylaxis and Treatment of Invasive Fungal Infections in Neutropenic Cancer and Hematopoietic Stem Cell Transplant Patients

Perfect¹

2009

Antifungal Therapy

View full text Add to dashboard Cite

Successful allogeneic haematopoietic stem cell transplantation in patients with poor-risk leukaemia and prior invasive fungal infection

Cited by 3 publications

References 7 publications

Post-transplant infections: single center experience from the developing world

Post-transplant infections: single center experience from the developing world

Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents

Prophylaxis and Treatment of Invasive Fungal Infections in Neutropenic Cancer and Hematopoietic Stem Cell Transplant Patients

Contact Info

Product

Resources

About